This study tests whether adding afuresertib to the standard hormone therapy fulvestrant can help people with a certain type of advanced breast cancer (HR+/HER2-) that has stopped responding to usual treatments. About 256 adults whose cancer has specific genetic changes (PIK3CA/AK…
Phase: PHASE3 • Sponsor: Laekna Limited • Aim: Disease control
Last updated May 14, 2026 12:02 UTC